Dual antiplatelet therapy with prasugrel or ticagrelor versus clopidogrel in interventional cardiology (Q38079124)

28 August 2017

1 reference

title

Dual antiplatelet therapy with prasugrel or ticagrelor versus clopidogrel in interventional cardiology (English)

1 reference

28 August 2017

1 reference

Peter Clemmensen

1

1 reference

PubMed ID

23380983

28 August 2017

Nadia Paarup Dridi

series ordinal

2

1 reference

PubMed ID

23380983

28 August 2017

Lene Holmvang

series ordinal

3

1 reference

28 August 2017

1 June 2013

1 reference

Cardiovascular Drugs and Therapy

28 August 2017

1 reference

28 August 2017

27

1 reference

28 August 2017

239-245

1 reference

28 August 2017

3

1 reference

Experience with revascularization procedures does matter: low volume means worse outcome

28 August 2017

1 reference

https://api.crossref.org/works/10.1007%2FS10557-013-6444-2

Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-013-6444-2

Current concepts on antiplatelet therapy: focus on the novel thienopyridine and non-thienopyridine agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-013-6444-2

Prasugrel versus clopidogrel in patients with acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-013-6444-2

Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-013-6444-2

Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-013-6444-2

Prasugrel versus clopidogrel for acute coronary syndromes without revascularization

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-013-6444-2

New P2Y12 inhibitors versus clopidogrel in percutaneous coronary intervention: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-013-6444-2

Adjusted indirect comparison meta-analysis of prasugrel versus ticagrelor for patients with acute coronary syndromes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-013-6444-2

Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: A Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-013-6444-2

Ticagrelor versus clopidogrel in patients with acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-013-6444-2

Efficacy and safety of clopidogrel pretreatment before percutaneous coronary intervention with and without glycoprotein IIb/IIIa inhibitor use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-013-6444-2

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-013-6444-2

A pharmacodynamic comparison of prasugrel vs. high-dose clopidogrel in patients with type 2 diabetes mellitus and coronary artery disease: results of the Optimizing anti-Platelet Therapy In diabetes MellitUS (OPTIMUS)-3 Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-013-6444-2

Diabetes and antiplatelet therapy in acute coronary syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-013-6444-2

Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-Thrombolysis in Myocar

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-013-6444-2

Ticagrelor vs. clopidogrel in patients with acute coronary syndromes and diabetes: a substudy from the PLATelet inhibition and patient Outcomes (PLATO) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-013-6444-2

Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a r

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-013-6444-2

Early and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a TRITON-TIMI 38 (TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel-Thro

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-013-6444-2

Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myoc

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-013-6444-2

Bleeding complications with the P2Y12 receptor antagonists clopidogrel and ticagrelor in the PLATelet inhibition and patient Outcomes (PLATO) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-013-6444-2

Increased platelet inhibition after switching from maintenance clopidogrel to prasugrel in patients with acute coronary syndromes: results of the SWAP (SWitching Anti Platelet) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-013-6444-2

Prasugrel compared with high-dose clopidogrel in acute coronary syndrome. The randomised, double-blind ACAPULCO study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-013-6444-2

Ticagrelor versus genotype-driven antiplatelet therapy for secondary prevention after acute coronary syndrome: a cost-effectiveness analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-013-6444-2

A systematic review of the associations between dose regimens and medication compliance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-013-6444-2

Present treatment of acute myocardial infarction in patients over 75 years--data from the Berlin Myocardial Infarction Registry (BHIR).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-013-6444-2

Bridging antiplatelet therapy with cangrelor in patients undergoing cardiac surgery: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-013-6444-2

Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-013-6444-2

Antithrombotic management of atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing coronary stenting: executive summary--a Consensus Document of the European Society of Cardiology Working Group on Thrombosis, endorse

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-013-6444-2

Clopidogrel pre-treatment is associated with reduced in-hospital mortality in primary percutaneous coronary intervention for acute ST-elevation myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-013-6444-2

10.1007/S10557-013-6444-2

21 January 2018

Identifiers

DOI

1 reference

28 August 2017

1 reference

PubMed ID

23380983